The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta-analysis.
AUC
CYP3A4
antiepileptic drugs
drug interactions
systematic review and meta-analysis
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
revised:
24
10
2023
received:
15
09
2023
accepted:
07
11
2023
pubmed:
27
11
2023
medline:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Antiseizure medications (ASMs) are commonly categorized as enzyme-inducers and non-enzyme-inducers based on their propensity to enhance the metabolism of concomitantly administered drugs. This systematic review and network meta-analysis aimed to rank ASMs as cytochrome P450 3A (CYP3A)-inducers based on a comparative assessment of ASM-induced reduction in the concentrations of sensitive substrate drugs. The protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews; CRD42022335846), and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) standards were followed. We searched MEDLINE, Embase, and Cochrane until March 14, 2023 without an initial date restriction. Data were additionally obtained via the US Food and Drug Administration database. Studies had to be prospective, with ASM monotherapy for ≥5 days. The primary parameter was the magnitude of change in the area under the concentration-time curve of CYP3A substrates following treatment with the ASM. The standardized mean difference (SMD) was used as the point estimate for the indirect comparisons between ASMs using the pairwise method. Bias risk was assessed using the PKclin tool. We identified 14 open-label, fixed-sequence studies with 370 participants. The effect size of 600 mg/day carbamazepine did not differ from those of 300 mg/day phenytoin (SMD = -.06, 95% confidence interval [CI] = -.18 to .07) and 200 mg/day cenobamate (SMD = -.11, 95% CI = -.26 to .04). Carbamazepine at 600 mg/day was the strongest CYP3A-inducer (P-score = .88), followed by carbamazepine 400 mg/day (.83), phenytoin 300 mg/day (.79), and cenobamate 200 mg/day (.73). Eslicarbazepine (800 mg/day) ranked higher than cenobamate 100 mg/day and oxcarbazepine 900 mg/day (.60, .39, and .37, respectively). Despite the limited number of studies, our network meta-analysis emphasizes that the magnitude of ASM effects on CYP3A substrate metabolism is a dose-dependent continuum. When possible, ASM classification as inducers should apply cutoff values tailored to the outcome. Prescribers should monitor plasma concentrations or clinical effects of CYP3A substrates and consider selecting concomitant medications accordingly.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Devinsky O, Vezzani A, O'Brien TJ, Jette N, Scheffer IE, de Curtis M, et al. Epilepsy. Nat Rev Dis Primers. 2018;4:18024.
Gogou M, Cross JH. Seizures and epilepsy in childhood. Continuum. 2022;28(2):428-456.
Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119-140.
Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review. JAMA. 2022;327(13):1269-1281.
Zaccara G, Lattanzi S, Brigo F. Which treatment strategy in patients with epilepsy with focal seizures uncontrolled by the first anti-seizure medication? Epilepsy Behav. 2021;121:108031.
Johannessen LC. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22(1):27-47.
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-255.
Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology. 2009;72:419-425.
Josephson CB, Gonzalez-Izquierdo A, Denaxas S, Sajobi TT, Klein KM, Wiebe S. Independent associations of incident epilepsy and enzyme-inducing and non-enzyme-inducing Antiseizure medications with the development of osteoporosis. JAMA Neurol. 2023;80:843-850.
Josephson CB, Wiebe S, Delgado-Garcia G, Gonzalez-Izquierdo A, Denaxas S, Sajobi TT, et al. Association of enzyme-inducing antiseizure drug use with long-term cardiovascular disease. JAMA Neurol. 2021;78(11):1367-1374.
Larsson D, Baftiu A, Johannessen Landmark C, von Euler M, Kumlien E, Åsberg S, et al. Association between Antiseizure drug monotherapy and mortality for patients with poststroke epilepsy. JAMA Neurol. 2022;79(2):169-175.
Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al. Effect of enzyme-inducing antiseizure medications on the risk of sub-therapeutic concentrations of direct oral anticoagulants: a retrospective cohort study. CNS Drugs. 2021;35(3):305-316.
Perlman A, Wanounou M, Goldstein R, Choshen Cohen L, Singer DE, Muszkat M. Ischemic and thrombotic events associated with concomitant Xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA Adverse Event Reporting System (FAERS). CNS Drugs. 2019;33(12):1223-1228.
van der Meer PB, Maschio M, Dirven L, Taphoorn MJB, Koekkoek JAF. First-line levetiracetam versus enzyme-inducing antiseizure medication in glioma patients with epilepsy. Epilepsia. 2023;64(1):162-169.
Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George JM, et al. Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS: report of the quality standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology. 2012;78:139-145.
Cokley JA, Gidal BE, Keller JA, Vossler DG. Paxlovid(TM) information from FDA and guidance for AES members. Epilepsy Curr. 2022;22(3):201-204.
Noyman I, Ekstein D, Fahoum F, Herskovitz M, Linder I, Ben Zeev B, et al. Using nirmatrelvir/ritonavir in patients with epilepsy: an update from the Israeli chapter of the international league against epilepsy. Epilepsia. 2022;63(5):1276-1278.
Wanounou M, Caraco Y, Levy RH, Bialer M, Perucca E. Clinically relevant interactions between ritonavir-boosted nirmatrelvir and concomitant antiseizure medications: implications for the management of COVID-19 in patients with epilepsy. Clin Pharmacokinet. 2022;61(9):1219-1236.
Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 2013;54(s9):97-104.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-141.
Patsalos P. Antiepileptic drug interactions. 3rd ed. Cham: Springer; 2023.
Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2012;54:11-27.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777-784.
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.
FDA. Drug development and drug interactions|table of substrates, inhibitors and inducers. 2022 [cited 2023 Mar 20]. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
FDA. Drugs@FDA: FDA-approved drugs. 2023 [cited 2023 Mar 27]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
FDA. In vitro drug interaction studies-cytochrome P450 enzyme- and transporter-mediated drug interactions. Guidance for industry. 2020 [cited 2023 Jun 23]. Available from: https://www.fda.gov/media/134582/download
Ramsden D, Fung C, Hariparsad N, Kenny JR, Mohutsky M, Parrott NJ, et al. Perspectives from the innovation and quality consortium induction working group on factors impacting clinical drug-drug interactions resulting from induction: focus on cytochrome 3a substrates. Drug Metab Dispos. 2019;47(10):1206-1221.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.
Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783-795.
Abdel Jalil MH, Abdullah N, Alsous MM, Saleh M, Abu-Hammour K. A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. Br J Clin Pharmacol. 2020;86(7):1267-1280.
Setiawan E, Cotta MO, Roberts JA, Abdul-Aziz MH. A systematic review on antimicrobial pharmacokinetic differences between Asian and non-Asian adult populations. Antibiotics. 2023;12(5), 803.
Schünemann HJ, Vist GE, Higgins JPT, Santesso N, Deeks JJ, Glasziou P, et al. Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.3. London, UK: Cochrane; 2022 [cited 2023 Apr 12]. Available from: www.training.cochrane.org/handbook
Higgins JPT, Deeks JJ. Selecting studies and collecting data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.3. London, UK: Cochrane; 2022 [cited 2023 Apr 12]. Available from: www.training.cochrane.org/handbook
Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.
Adiwidjaja J, Boddy AV, McLachlan AJ. A strategy to refine the phenotyping approach and its implementation to predict drug clearance: a physiologically based pharmacokinetic simulation study. CPT Pharmacometrics Syst Pharmacol. 2018;7(12):798-808.
Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther. 1989;249(2):638-645.
Favié LMA, Groenendaal F, van den Broek MPH, Rademaker CMA, de Haan TR, van Straaten HLM, et al. Phenobarbital, midazolam pharmacokinetics, effectiveness, and drug-drug interaction in asphyxiated neonates undergoing therapeutic hypothermia. Neonatology. 2019;116(2):154-162.
Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, et al. Cytochrome P450 3A induction predicts P-glycoprotein induction; part 1: establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther. 2018;104(6):1182-1190.
FDA. PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use. 2023 [cited 2023 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf
Guy-Alfandary S, Zhurat S, Berlin M, de Haan T, Gueta I, Shihmanter R, et al. Managing potential drug interactions of nirmatrelvir/ritonavir in COVID-19 patients: a perspective from an Israeli cross-sector collaboration. Clin Pharmacol Ther. 2022;112(6):1156-1158.
Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, et al. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (paxlovid) and comedications. Clin Pharmacol Ther. 2022;112(6):1191-1200.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23(10):1612-1676.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
Kudriakova TB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol. 1992;33(6):611-615.
FDA (USA Food and Drug Administration). Xcopri (cenobamate). 2022.
FDA. APTIOM® (eslicarbazepine acetate) tablets, for oral use. 2019 [cited 2023 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022416s011lbl.pdf
Goldstein R, Jacobs AR, Zighan L, Gronich N, Bialer M, Muszkat M. Interactions between Direct Oral Anticoagulants (DOACs) and antiseizure medications: potential implications on DOAC treatment. CNS Drugs. 2023;37(3):203-214.
Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61(1):58-69.
Grimm SW, Stams KR, Bui K. 559-In vitro prediction of potential metabolic drug interactions for seroquel. Schizophr Res. 1997;24(1):198.
Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G. Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.3. London, UK: Cochrane; 2022 [cited 2023 Apr 12]. Available from: www.training.cochrane.org/handbook